Nuclear Safeguards Bill

Debate between Simon Hoare and Jo Churchill

2nd reading: House of Commons
Monday 16th October 2017 Commons Chamber

[Simon Hoare]

The hon. Lady falls into a classic trap. I am not one who seeks to dismiss experts—as a non-expert, I always turn to experts for advice—but a concern that is wrong in fact does not become legitimate if it is raised by an expert. A person could be concerned about all sorts of things, and they could have as many letters after their name as they like, but they are not always correct. Some Opposition Members started to fan the embers of this flame about three or four months ago, and it does not appear to have caught.

I have received a briefing note, as I am sure have other colleagues, entitled “What about medical radioisotopes?” The import or export of medical radioisotopes is not subject to any Euratom licensing requirements. Let us seek to assure the experts who have concerns—their concerns are legitimate, and the House must address them—that Euratom places no restrictions on the export of medical isotopes to countries outside the EU. These isotopes are not subject to Euratom supply agency contracts or to Euratom safeguards, which means no special arrangements need to be put in place ahead of withdrawal.

Withdrawal from Euratom will have no effect on the UK’s ability to import medical isotopes from Europe and the rest of the world. It is in everyone’s interest not to disrupt patients’ timely access to treatment, and it is in everyone’s interest to ensure that cross-border trade with the EU is as frictionless as possible. I entirely take the point raised by several hon. Members, including the hon. Member for Inverness, Nairn, Badenoch and Strathspey (Drew Hendry), that some of these products have a short shelf life, and clearly we cannot have these products sitting in an overheated metal container at the port of Dover or Calais.

Out of common sense I have to ask which country on God’s earth will set a tariff barrier regime and seek to take beyond its useful lifespan a vital component in the delivery of medical care. In the French Government, the German Government and the Belgian Government, we are not dealing with countries that have no interest in public health and healthcare, because of course they do, as do our Government. The idea that those countries will deliberately set up barriers that cause these products to pass their sell-by date, like a piece of chicken that has been sat too long on a supermarket shelf, is fanciful and compounds the allegation that I and several of my hon. Friends have made, that the Bill can be criticised for other reasons, but it is cruel, callous and unnecessary to criticise it at the expense of unsettling people who require medical interventions.

[Jo Churchill (Bury St Edmunds) (Con)]

I thank my hon. Friend for largely making my point for me. He knows my deep interest in this area, and I draw to his attention the fact that not only has the Secretary of State reiterated those points today but that the Minister for Universities, Science, Research and Innovation firmly made them back in June.

Are the expert opinions that my hon. Friend is addressing recent, or are they historical?

[Simon Hoare]

My hon. Friend makes a valid point. These debates often get stuck in a groove on the gramophone, the needle gets stuck and we do not knock it forward. I think it was John Maynard Keynes who said, “When the facts change, I change my mind.” A concern is raised, it is addressed, it ceases to be a concern and we move on to something else. I am not saying there will be no other concerns.